NCT07220083
A Study to Find Out if BI 764198 Helps Adults and Adolescents With a Kidney Condition Called Focal Segmental Glomerulosclerosis (FSGS)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 32 versions: 32 with changes below. See every version on ClinicalTrials.gov ↗
- Minor Trial sites reduced: 316 → 309 locations
- Minor Study sites: 316 to 315
- Secondary endpoints: details revised at 1 of 6 entries
- Minor Study sites revised (316)
- Minor Trial sites expanded: 311 → 316 locations
- Minor Trial sites expanded: 307 → 311 locations
- Notable Eligibility criteria expanded, about 15 words
- Primary endpoints: details revised at 1 of 1 entry
- Study sites: 309 to 307
- Secondary endpoints: details revised at 6 of 6 entries
- Minor Trial sites expanded: 306 → 309 locationsv26
- Minor Trial sites expanded: 302 → 306 locationsv25
- Minor Trial sites expanded: 296 → 302 locationsv24
- Minor Study sites: 294 to 296v23
- Notable Primary endpoint(s) modified
- Eligibility criteria shortened, about 4 words
- Trial sites expanded: 287 → 294 locations
- Secondary endpoints: details revised at 2 of 6 entries
- Minor Trial sites expanded: 277 → 287 locations
- Primary completion moved earlier from Nov 20, 2029 to Dec 27, 2028
- Study completion moved earlier from Dec 18, 2029 to Jan 24, 2029
- Minor Trial sites expanded: 271 → 277 locationsv20
- Minor Trial sites expanded: 266 → 271 locationsv19
- Minor Trial sites expanded: 256 → 266 locationsv18
- Minor Study sites: 254 to 256v17
- Minor Trial sites expanded: 251 → 254 locationsv16
- Minor Trial sites expanded: 243 → 251 locationsv15
- Minor Study sites: 231 to 243v14
- Minor Study sites: 211 to 231v13
- Notable Trial status: Not Yet Recruiting to Recruiting
- Study sites: 205 to 211
- Start date changed from estimate of Feb 6, 2026 to Feb 16, 2026
- Minor Study sites: 204 to 205
- Start date: Jan 31, 2026 to Feb 6, 2026
- Minor Study sites: 194 to 204
- Start date: Jan 23, 2026 to Jan 31, 2026
- Minor Study sites: 187 to 194v9
- Notable Start date: Dec 19, 2025 to Jan 23, 2026
- Study sites: 185 to 187
- Minor Study sites: 183 to 185v7
- Minor Site contacts updated at 10 of 183 sitesv6
- Minor Study sites: 178 to 183
- Start date: Dec 5, 2025 to Dec 19, 2025
- Minor Study sites: 173 to 178v4
- Minor Study sites: 156 to 173
- Primary completion date: Feb 20, 2030 to Nov 20, 2029
- Study completion date: Mar 20, 2030 to Dec 18, 2029
- Minor Study sites: 0 to 156v2
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Relative change in 24-hour UPCR (measured in mg/g) from baseline to Week 104
Timeframe: Baseline and Week 104
Secondary (6)
Key secondary endpoint: Absolute change in eGFRcys in mL/min/1.73m2 from baseline to Week 104
Key secondary endpoint: Treatment response, defined as 24-hr UPCR <1000 mg/g at Week 104
Treatment response, defined as 24-hr UPCR <1000 mg/g and eGFRcys ≥85% vs. baseline at Week 104 and no treatment failure between randomisation and Week 104 (combined or multi-component endpoint)
Complete remission, defined as 24-hr UPCR <300 mg/g at Week 104
Change from baseline across disease-specific clinical outcome assessment (COA) NS-SIM-PRO at Week 104
Show 1 moreShow less
Change from baseline across clinical outcome assessment (COA) KDQOL-36 at Week 104
Arms and interventions
BI 764198 treatmentExperimental
Placebo treatmentExperimental
Drugs: BI 764198, Placebo
Sites
309 sites in 37 countries
United States 75, China 22, India 19, Japan 19, Turkey (Türkiye) 11, Portugal 10, Argentina 9, Australia 9, France 9, Taiwan 9, United Kingdom 9, Germany 8, Brazil 7, Poland 7, Spain 7, Italy 6, Malaysia 6, Mexico 6, South Korea 6, Canada 5, Slovakia 5, Sweden 5, Croatia 4, New Zealand 4, Norway 4, Romania 4, Belgium 3, Georgia 3, Singapore 3, Denmark 2, Greece 2, Hong Kong 2, Netherlands 2, Saudi Arabia 2, Switzerland 2, Thailand 2, Philippines 1